HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostic products, today announced that NF Validation (AFNOR) has approved the extension of certification of the iQ-Check™ Listeria spp. and iQ-Check™ Listeria monocytogenes Kits for the real-time PCR detection of Listeria spp. and Listeria monocytogenes in food products for human consumption and in environmental samples with a short enrichment protocol using Listeria Special Broth II (LSB II).

The new shortened protocol uses LSB II, a next-generation enrichment broth designed specifically to resuscitate Listeria, reducing both enrichment and overall time to results in less than 24 hr. In comparison to the reference method, ISO 11290-1, the protocol demonstrated excellent results following evaluation for sensitivity, relative level of detection, inclusivity and exclusivity.

NF Validation is an international certification organization for the validation and approval of alternative methods for the microbiological analysis of food and beverages. The technical protocol and result interpretation for this study were carried out according to the ISO-16140-2/ADM1:2024 and AFNOR technical rules.

The iQ-Check Listeria spp. and iQ-Check Listeria monocytogenes LSB II enrichment short protocol methods are also approved by AOAC INTERNATIONAL.

Listeria are gram-positive bacteria responsible for listeriosis, a serious infection especially harmful for pregnant women, newborns, older adults, and people with weakened immune systems. Primarily found in soil, water, and animal products, accurate detection of contamination in both food and environmental samples is critical in ensuring the production of safe consumables.

The certificates are available at bio-rad.com/validations

For more information on Bio-Rad’s complete range of iQ-Check Real-Time PCR Test Kits, please visit bio-rad.com/iqcheck

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.